AUAUniversity

Incorporating Genomic Testing For Prostate Cancer into Your Practice (2021) CME Available: https://auau.auanet.org/node/31455 ACKNOWLEDGEMENTS Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme. At the conclusion of the activity, pa...

This podcast webinar will introduce attendees to current diversity initiatives within urology. Panelists representing these programs will discuss the benefits of promoting diversity in urology, how their initiatives began, available resources and what urology residency programs and medical schools can do to promote diversity.

How to Manage a 65 Year Old Man with Bothersome LUTS and Underactive Bladder by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31224 Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Modera...

Multidisciplinary Discussion On Fertility, Hypogonadism & Sexual Function For Testis Cancer Patients by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31223 Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Modera...

Controversies In Urology - Robotic Kidney Transplantation by American Urological Association

Panel Discussion - Infection And Urologic Implants by American Urological Association

This educational series is supported by independent educational grants from AstraZeneca and Merck. CME Available: https://auau.auanet.org/node/31198 Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the ser...

This educational series is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Pfizer, Inc. CME Available: https://auau.auanet.org/node/30861 In 2020, the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline was released and will provide critical guidance as the management of advanced prostate cancer patients continues...

Impacts of COVID-19 on Urology Training and Education by American Urological Association

Crossfire In Urology - Robotic Reconstruction by American Urological Association

At the conclusion of this activity, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options. 2.Describe the mechanism of action and associated side effects of the new adjuvant therapy. 3. Differentiate the roles between the urologist and medical onco...

AUA Guidelines Case - Based Panel Stress Urinary Incontinence by American Urological Association

Panel Discussion - Peyronie's Disease Management by American Urological Association

Pain Management In Urologic Surgery by American Urological Association

Bulbar Urethral Strictures 101 - A Review Of The Guidelines And Basic Management Options by American Urological Association

Learning Objective: At the conclusion of this continuing medical education activity, the participant will be able to select different strategies for ureteroscopic renal stone surgery, determine how laser parameter selection can improve lithotripsy efficiency and identify the important safety considerations to optimize patient outcomes.

At the conclusion of this activity, participants will be able to: 1. Explain the sequencing of novel therapies and be able to identify patient progression of disease. 2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. This educational series is supported by independent educational grants from: Astellas Astra...

At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options. This educational series is supported...

Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020) Presented by Leonard Gomella, MD and Joshua Lang, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Aff...

Presented by Kelly Stratton, MD and Alicia Morgans, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30123

Case-Based Discussion: BCR and mHSPC and M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD This educational activity is supported by independent educational grants from: AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. CME Available: https://auau.auanet.org/node/30122

At the conclusion of this activity, participants will be able to: 1. Identify the role of genetic testing in men with advanced, metastatic and CRPC. 2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision m...

At the conclusion of this activity, participants will be able to: 1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care. 2. Identify important causes for disparities as well as possible remedies to address these causes. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc.,...